Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473168 | 0.76 | CA2 (0.41) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL16749114 | 0.76 | ALDH1A1 (0.45) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL13295517 | 0.76 | ALDH1A1 (0.45) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL24500002 | 0.73 | CA1 (0.32) | CA2CA1CA9 | |
| SCHEMBL12858933 | 0.72 | PI4KA (0.38) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL24686930 | 0.72 | PI4KA (0.38) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL12838397 | 0.72 | PI4KA (0.38) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL17110046 | 0.72 | PI4KA (0.38) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL10072844 | 0.72 | PI4KA (0.38) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL20131364 | 0.72 | PI4KA (0.38) | CA2CA1CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177510-A1 | DERIVATIVES OF GYLCERO-MANNO-HEPTOSE ADP FOR USE IN MODULATING IMMUNE RESPONSE | GALK1, PHKA1, PGK1 | CA2 3503/4885CA1 4300/4885CA9 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.